Edition:
United States

Profile: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

4.19USD
25 Sep 2017
Change (% chg)

-- (--)
Prev Close
$4.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,898,983
52-wk High
$8.86
52-wk Low
$3.15

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Company Address

Achillion Pharmaceuticals Inc

300 George St
NEW HAVEN   CT   06511-6624
P: +1203.6247000
F: +1203.6247003

Company Web Links